TDMS Study 05111-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1,2,3-TRICHLOROPROPANE
NTP Experiment-Test: 05111-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/14/94
Route: GAVAGE Time: 05:10:27
Facility: TSI Mason Research
Chemical CAS #: 96-18-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 8 8
Early Deaths
Moribund 17 17 42 50
Dead 2 2 2 2
Survivors
Terminal Sacrifice 31 30 8
Wrong Sex 1
Animals Examined Microscopically 60 59 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (59) (57) (60) (59)
Adenocarcinoma 1 (2%)
Intestine Small, Jejunum (59) (57) (60) (60)
Adenocarcinoma 1 (2%) 2 (3%)
Liver (60) (59) (60) (60)
Hepatocellular Adenoma 1 (2%)
Sarcoma, Metastatic, Pharynx 1 (2%)
Mesentery (2) (5) (4) (1)
Nephroblastoma, Metastatic, Kidney 1 (100%)
Pancreas (60) (59) (60) (60)
Acinus, Adenoma 2 (3%)
Pharynx (1) (3) (18) (23)
Squamous Cell Carcinoma 1 (4%)
Palate, Squamous Cell Carcinoma 1 (33%) 10 (56%) 15 (65%)
Palate, Squamous Cell Papilloma 1 (100%) 2 (67%) 5 (28%) 3 (13%)
Salivary Glands (60) (59) (60) (60)
Stomach, Forestomach (60) (59) (59) (60)
Squamous Cell Carcinoma 3 (5%) 6 (10%) 4 (7%)
Squamous Cell Carcinoma, Multiple 3 (5%) 2 (3%)
Squamous Cell Papilloma 10 (17%) 30 (51%) 19 (32%)
Squamous Cell Papilloma, Multiple 4 (7%) 7 (12%) 5 (8%)
Stomach, Glandular (60) (59) (60) (59)
Tongue (10) (4) (21) (35)
Squamous Cell Carcinoma 13 (62%) 8 (23%)
Squamous Cell Papilloma 3 (75%) 5 (24%) 18 (51%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (59) (60) (58)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (59) (58) (60) (57)
Adenoma 1 (2%)
Adrenal Gland, Medulla (59) (56) (59) (57)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Pheochromocytoma Malignant 2 (3%)
Pheochromocytoma Benign 5 (8%) 2 (4%) 1 (2%)
Islets, Pancreatic (60) (58) (60) (60)
Adenoma 2 (3%) 2 (3%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Pituitary Gland (60) (58) (59) (59)
Pars Distalis, Adenoma 29 (48%) 30 (52%) 12 (20%) 5 (8%)
Thyroid Gland (60) (57) (60) (60)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 4 (7%) 4 (7%) 4 (7%)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 3 (5%) 2 (3%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (56) (56) (58) (59)
Adenoma 4 (7%) 11 (20%) 11 (19%) 12 (20%)
Carcinoma 3 (5%) 5 (8%)
Bilateral, Adenoma 1 (2%) 3 (5%)
Bilateral, Carcinoma 1 (2%) 1 (2%)
Ovary (60) (58) (60) (60)
Nephroblastoma, Metastatic, Kidney 1 (2%)
Thecoma Benign 1 (2%)
Bilateral, Hemangioma 1 (2%)
Uterus (60) (58) (60) (60)
Hemangioma 1 (2%)
Polyp Stromal 7 (12%) 4 (7%) 6 (10%) 1 (2%)
Sarcoma 1 (2%) 1 (2%)
Sarcoma Stromal 3 (5%)
Page 3
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Bilateral, Polyp Stromal 2 (3%) 1 (2%) 1 (2%)
Endometrium, Adenoma 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (5) (4) (3)
Bone Marrow (60) (58) (60) (60)
Lymph Node (60) (59) (60) (60)
Mediastinal, Sarcoma, Metastatic, Pharynx 1 (2%)
Lymph Node, Mandibular (58) (57) (60) (58)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Sarcoma, Metastatic, Pharynx 1 (2%)
Squamous Cell Carcinoma, Metastatic, Pharynx 1 (2%) 1 (2%)
Lymph Node, Mesenteric (60) (58) (59) (57)
Spleen (60) (57) (60) (59)
Sarcoma, Metastatic, Pharynx 1 (2%)
Thymus (56) (56) (59) (57)
Epithelial Cell, Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (57) (55) (53) (50)
Adenocarcinoma 1 (2%) 6 (11%) 11 (21%) 20 (40%)
Adenocarcinoma, Multiple 1 (2%) 2 (4%)
Adenoma 1 (2%) 2 (4%) 1 (2%)
Adenoma, Multiple 1 (2%)
Fibroadenoma 13 (23%) 15 (27%) 12 (23%) 1 (2%)
Fibroadenoma, Multiple 2 (4%) 8 (15%) 8 (15%)
Skin (60) (59) (59) (59)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (59) (60) (60)
Astrocytoma Malignant 1 (2%)
Peripheral Nerve (2)
Squamous Cell Carcinoma, Metastatic, Pharynx 2 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (58) (59) (60)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%) 1 (2%) 2 (3%)
Alveolar/Bronchiolar Adenoma 2 (3%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Pharynx 1 (2%)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (2)
Sarcoma 1 (100%)
Eye (4) (5) (11) (19)
Histiocytic Sarcoma 1 (5%)
Harderian Gland (1) (1) (9)
Adenoma 1 (11%)
Zymbal's Gland (1) (4)
Carcinoma 1 (100%) 4 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (57) (60) (59)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma, Metastatic 1 (2%)
Nephroblastoma 1 (2%)
Renal Tubule, Adenocarcinoma 1 (2%)
Urinary Bladder (59) (56) (60) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(59) *(60) *(60)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 13 (22%) 17 (29%) 14 (23%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49 50 56 56
Total Primary Neoplasms 96 135 189 138
Total Animals with Benign Neoplasms 42 48 51 40
Total Benign Neoplasms 74 102 119 70
Total Animals with Malignant Neoplasms 20 25 46 48
Total Malignant Neoplasms 22 33 70 68
Total Animals with Metastatic Neoplasms 1 3 7
Total Metastatic Neoplasm 5 3 13
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 9
Early Deaths
Moribund 13 16 30 43
Dead 2 2 4
Accident 1 1
Survivors
Terminal Sacrifice 34 32 14
Wrong Sex 1
Animals Examined Microscopically 60 60 59 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (60) (60) (58) (60)
Adenocarcinoma, Multiple 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Large, Rectum (59) (60) (57) (60)
Polyp Adenomatous 1 (2%)
Intestine Small, Duodenum (59) (60) (58) (60)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Intestine Small, Ileum (59) (60) (57) (59)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Intestine Small, Jejunum (59) (60) (57) (60)
Adenocarcinoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Liver (60) (60) (59) (60)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Hepatocellular Carcinoma 1 (2%) 2 (3%)
Hepatocellular Adenoma 1 (2%) 1 (2%) 3 (5%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 2 (3%)
Mesentery (5) (9) (12) (5)
Sarcoma, Metastatic, Skin 1 (20%)
Pancreas (60) (60) (59) (60)
Adenoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Mixed Tumor Benign 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (2%)
Acinus, Adenocarcinoma 2 (3%) 1 (2%)
Acinus, Adenoma 5 (8%) 7 (12%) 6 (10%) 5 (8%)
Acinus, Adenoma, Multiple 14 (23%) 31 (53%) 25 (42%)
Page 7
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pharynx (1) (5) (18) (16)
Palate, Squamous Cell Carcinoma 1 (100%) 11 (61%) 7 (44%)
Palate, Squamous Cell Papilloma 2 (40%) 1 (6%) 4 (25%)
Salivary Glands (60) (60) (59) (60)
Adenoma 1 (2%)
Stomach, Forestomach (60) (60) (59) (60)
Squamous Cell Carcinoma 9 (15%) 18 (31%) 13 (22%)
Squamous Cell Carcinoma, Multiple 10 (17%) 1 (2%)
Squamous Cell Papilloma 19 (32%) 27 (46%) 32 (53%)
Squamous Cell Papilloma, Multiple 12 (20%) 9 (15%) 14 (23%)
Stomach, Glandular (60) (60) (59) (60)
Tongue (14) (8) (13) (47)
Squamous Cell Carcinoma 19 (40%)
Squamous Cell Papilloma 2 (25%) 9 (69%) 18 (38%)
Squamous Cell Papilloma, Multiple 3 (6%)
Tooth (1) (1)
Adamantinoma Benign 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (59) (59) (60)
Carcinoma, Metastatic, Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60) (58) (59)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Bilateral, Medulla, Osteosarcoma, Metastatic,
Bone 1 (2%)
Adrenal Gland, Medulla (59) (60) (58) (59)
Pheochromocytoma Malignant 1 (2%) 1 (2%) 2 (3%)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 8 (14%) 7 (12%) 12 (21%)
Bilateral, Pheochromocytoma Benign 2 (3%) 1 (2%)
Islets, Pancreatic (60) (60) (59) (60)
Adenoma 9 (15%) 4 (7%) 3 (5%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (58) (58) (59) (59)
Pars Distalis, Adenoma 9 (16%) 14 (24%) 8 (14%) 2 (3%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Distalis, Fibrous Histiocytoma,
Metastatic, Kidney 1 (2%)
Thyroid Gland (60) (59) (59) (59)
Page 8
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Sarcoma, Metastatic, Skin 1 (2%)
C-Cell, Adenoma 4 (7%) 14 (24%) 4 (7%) 6 (10%)
C-Cell, Adenoma, Multiple 1 (2%)
C-Cell, Carcinoma 1 (2%) 2 (3%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 2 (3%) 2 (3%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (59) (59) (60)
Sarcoma, Metastatic, Skin 1 (2%)
Penis (1)
Squamous Cell Carcinoma 1 (100%)
Preputial Gland (59) (57) (59) (58)
Adenoma 5 (8%) 3 (5%) 6 (10%) 8 (14%)
Carcinoma 2 (4%) 3 (5%) 5 (9%)
Bilateral, Adenoma 3 (5%)
Bilateral, Carcinoma 1 (2%) 1 (2%)
Prostate (58) (60) (59) (60)
Adenoma 2 (3%)
Seminal Vesicle (59) (58) (58) (60)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (2%)
Testes (60) (60) (59) (60)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Bilateral, Interstitial Cell, Adenoma 43 (72%) 41 (68%) 42 (71%) 42 (70%)
Interstitial Cell, Adenoma 12 (20%) 13 (22%) 13 (22%) 10 (17%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (2) (3) (3)
Bone Marrow (60) (60) (59) (60)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Lymph Node (60) (60) (59) (60)
Mediastinal, Carcinoma, Metastatic, Thyroid
Gland 1 (2%)
Mediastinal, Fibrous Histiocytoma,
Page 9
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Metastatic, Kidney 1 (2%)
Renal, Fibrous Histiocytoma, Metastatic,
Kidney 1 (2%)
Lymph Node, Mandibular (60) (60) (58) (60)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Sarcoma, Metastatic, Ear 1 (2%)
Lymph Node, Mesenteric (60) (59) (57) (59)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Hemangioma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 2 (3%)
Spleen (60) (60) (59) (60)
Fibroma 2 (3%)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Hemangioma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Thymus (59) (58) (51) (56)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Epithelial Cell, Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (51) (50) (41) (46)
Fibroadenoma 2 (4%) 3 (6%) 1 (2%)
Fibroadenoma, Multiple 1 (2%)
Skin (60) (58) (58) (59)
Basal Cell Carcinoma 1 (2%)
Keratoacanthoma 2 (3%) 2 (3%) 1 (2%) 2 (3%)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 2 (3%) 5 (8%)
Trichoepithelioma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 2 (3%) 5 (9%) 1 (2%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (59) (60)
Osteosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Skeletal Muscle (2) (3) (5) (3)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (33%)
Fibrous Histiocytoma, Metastatic 1 (20%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (33%) 2 (40%) 1 (33%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (59) (59) (60)
Astrocytoma Malignant 1 (2%)
Glioma Malignant 1 (2%)
Peripheral Nerve (1)
Squamous Cell Carcinoma, Metastatic, Pharynx 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (59) (59) (60)
Alveolar/Bronchiolar Adenoma 2 (3%) 1 (2%) 2 (3%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma 1 (2%)
Fibrous Histiocytoma, Metastatic, Kidney 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%) 1 (2%)
Mediastinum, Squamous Cell Carcinoma,
Metastatic, Stomach 1 (2%)
Nose (60) (60) (59) (60)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2)
Sarcoma 1 (100%) 2 (100%)
Zymbal's Gland (4)
Carcinoma 3 (75%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (59) (60)
Fibrous Histiocytoma, Metastatic 1 (2%)
Sarcoma, Metastatic 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Renal Tubule, Adenoma 2 (3%) 10 (17%) 16 (27%)
Renal Tubule, Adenoma, Multiple 10 (17%) 10 (17%)
Renal Tubule, Oncocytoma Benign 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
Urinary Bladder (59) (60) (57) (60)
Page 11
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Melanoma Malignant, Metastatic, Testes 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(59) *(60)
Leukemia Mononuclear 16 (27%) 11 (18%) 9 (15%) 6 (10%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Mesothelioma Malignant 3 (5%) 4 (7%) 4 (7%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05111-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1,2,3-TRICHLOROPROPANE Date: 09/14/94
Route: GAVAGE Time: 05:10:27
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0 MG/KG 3 MG/KG 10 MG/KG 30 MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 58 58 57 60
Total Primary Neoplasms 138 202 287 286
Total Animals with Benign Neoplasms 57 58 56 57
Total Benign Neoplasms 112 168 212 220
Total Animals with Malignant Neoplasms 22 28 39 47
Total Malignant Neoplasms 26 34 75 66
Total Animals with Metastatic Neoplasms 5 7 10 5
Total Metastatic Neoplasm 23 20 45 10
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 80947-80947/80947
--multipart-boundary--